A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

Name: A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
Published: 2023
License: Public Domain

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

her2-positive advanced gastric cancer, her2-positive gastroesophageal junction adenocarcinoma, trastuzumab deruxtecan, conventional therapy, enhertu®, observational

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

Related documents